BioSenic S.A. (BIOS.BR)
Brussels · EUR · Healthcare · Biotechnology
€0.002 (+0.00%) as of
Key statistics
- Market cap
- 1.31M
- Forward P/E
- -0.04
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0018 – 0.0026
- Beta
- -1.58
- Revenue (TTM)
- -2.59M
- Profit margin
- 0.00%
- Volume
- 220.74k
About BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Saintes, Belgium
- Employees
- 7
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.